Zoster meningitis in an immunocompetent young patient post first dose of BNT162b2 mRNA COVID-19 vaccine, a case report
Recently published observational data suggests an increased risk of herpes zoster infection post-vaccination with the BNT162b2 mRNA vaccine. We describe the case of VZV meningitis post BNT162b2 mRNA vaccination in a young immunocompetent patient. A 39-year-old patient with no medical history present...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2022-01-01
|
| Series: | IDCases |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2214250922000804 |
| _version_ | 1819174654650089472 |
|---|---|
| author | Colm Kerr Susan O’Neill Anna Szucs Oliver Darmody Claire Williamson Ciaran Bannan Concepta Merry |
| author_facet | Colm Kerr Susan O’Neill Anna Szucs Oliver Darmody Claire Williamson Ciaran Bannan Concepta Merry |
| author_sort | Colm Kerr |
| collection | DOAJ |
| description | Recently published observational data suggests an increased risk of herpes zoster infection post-vaccination with the BNT162b2 mRNA vaccine. We describe the case of VZV meningitis post BNT162b2 mRNA vaccination in a young immunocompetent patient. A 39-year-old patient with no medical history presented with a vesicular rash, headache, nausea and fever, days after receiving BNT162b2 mRNA vaccination. CSF analysis revealed a pleocytosis, and VZV DNA was confirmed by PCR testing. The patient received intravenous aciclovir with resolution of symptoms within 48 h. He was discharged after 14 days of treatment. Case reports of herpes zoster reactivation post vaccination and details of subsequent successful vaccination course completion have allowed us to recommend the patient receive his second dose of the BNT162b2 mRNA vaccine. At the time of writing, however, the patient has declined to receive further vaccination due to fears of an adverse event. To the best of our knowledge, this is the first reported case in a young patient of herpes zoster meningitis following COVID-19 mRNA vaccination. The sharing of clinical experiences and reporting of suspected side effects, particularly for vaccines that employ novel technology, increases knowledge of the safety profile of these vaccines and allows clinicians to better aid patients make informed decisions with regard to commencing and completing vaccination. |
| first_indexed | 2024-12-22T20:42:25Z |
| format | Article |
| id | doaj.art-bacd486001894615a890d240d7fb92fd |
| institution | Directory Open Access Journal |
| issn | 2214-2509 |
| language | English |
| last_indexed | 2024-12-22T20:42:25Z |
| publishDate | 2022-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | IDCases |
| spelling | doaj.art-bacd486001894615a890d240d7fb92fd2022-12-21T18:13:18ZengElsevierIDCases2214-25092022-01-0127e01452Zoster meningitis in an immunocompetent young patient post first dose of BNT162b2 mRNA COVID-19 vaccine, a case reportColm Kerr0Susan O’Neill1Anna Szucs2Oliver Darmody3Claire Williamson4Ciaran Bannan5Concepta Merry6Department of Infectious Diseases, St James's Hospital, Dublin, Ireland; School of Medicine, Trinity College Dublin, Dublin, Ireland; Corresponding author at: Department of Infectious Diseases, St James’s Hospital, Dublin, Ireland.Department of Infectious Diseases, St James's Hospital, Dublin, IrelandDepartment of Infectious Diseases, St James's Hospital, Dublin, IrelandDepartment of Infectious Diseases, St James's Hospital, Dublin, IrelandDepartment of Infectious Diseases, St James's Hospital, Dublin, IrelandDepartment of Infectious Diseases, St James's Hospital, Dublin, Ireland; School of Medicine, Trinity College Dublin, Dublin, IrelandDepartment of Infectious Diseases, St James's Hospital, Dublin, Ireland; School of Medicine, Trinity College Dublin, Dublin, IrelandRecently published observational data suggests an increased risk of herpes zoster infection post-vaccination with the BNT162b2 mRNA vaccine. We describe the case of VZV meningitis post BNT162b2 mRNA vaccination in a young immunocompetent patient. A 39-year-old patient with no medical history presented with a vesicular rash, headache, nausea and fever, days after receiving BNT162b2 mRNA vaccination. CSF analysis revealed a pleocytosis, and VZV DNA was confirmed by PCR testing. The patient received intravenous aciclovir with resolution of symptoms within 48 h. He was discharged after 14 days of treatment. Case reports of herpes zoster reactivation post vaccination and details of subsequent successful vaccination course completion have allowed us to recommend the patient receive his second dose of the BNT162b2 mRNA vaccine. At the time of writing, however, the patient has declined to receive further vaccination due to fears of an adverse event. To the best of our knowledge, this is the first reported case in a young patient of herpes zoster meningitis following COVID-19 mRNA vaccination. The sharing of clinical experiences and reporting of suspected side effects, particularly for vaccines that employ novel technology, increases knowledge of the safety profile of these vaccines and allows clinicians to better aid patients make informed decisions with regard to commencing and completing vaccination.http://www.sciencedirect.com/science/article/pii/S2214250922000804COVID-19MRNAVaccineZosterMeningitis |
| spellingShingle | Colm Kerr Susan O’Neill Anna Szucs Oliver Darmody Claire Williamson Ciaran Bannan Concepta Merry Zoster meningitis in an immunocompetent young patient post first dose of BNT162b2 mRNA COVID-19 vaccine, a case report IDCases COVID-19 MRNA Vaccine Zoster Meningitis |
| title | Zoster meningitis in an immunocompetent young patient post first dose of BNT162b2 mRNA COVID-19 vaccine, a case report |
| title_full | Zoster meningitis in an immunocompetent young patient post first dose of BNT162b2 mRNA COVID-19 vaccine, a case report |
| title_fullStr | Zoster meningitis in an immunocompetent young patient post first dose of BNT162b2 mRNA COVID-19 vaccine, a case report |
| title_full_unstemmed | Zoster meningitis in an immunocompetent young patient post first dose of BNT162b2 mRNA COVID-19 vaccine, a case report |
| title_short | Zoster meningitis in an immunocompetent young patient post first dose of BNT162b2 mRNA COVID-19 vaccine, a case report |
| title_sort | zoster meningitis in an immunocompetent young patient post first dose of bnt162b2 mrna covid 19 vaccine a case report |
| topic | COVID-19 MRNA Vaccine Zoster Meningitis |
| url | http://www.sciencedirect.com/science/article/pii/S2214250922000804 |
| work_keys_str_mv | AT colmkerr zostermeningitisinanimmunocompetentyoungpatientpostfirstdoseofbnt162b2mrnacovid19vaccineacasereport AT susanoneill zostermeningitisinanimmunocompetentyoungpatientpostfirstdoseofbnt162b2mrnacovid19vaccineacasereport AT annaszucs zostermeningitisinanimmunocompetentyoungpatientpostfirstdoseofbnt162b2mrnacovid19vaccineacasereport AT oliverdarmody zostermeningitisinanimmunocompetentyoungpatientpostfirstdoseofbnt162b2mrnacovid19vaccineacasereport AT clairewilliamson zostermeningitisinanimmunocompetentyoungpatientpostfirstdoseofbnt162b2mrnacovid19vaccineacasereport AT ciaranbannan zostermeningitisinanimmunocompetentyoungpatientpostfirstdoseofbnt162b2mrnacovid19vaccineacasereport AT conceptamerry zostermeningitisinanimmunocompetentyoungpatientpostfirstdoseofbnt162b2mrnacovid19vaccineacasereport |